Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions?

Published:2024-06 Issue:6 Volume:22 Page:1186-1187
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Mahgoub Sara,Newsome Philip N.^ORCID

Publisher

Elsevier BV

Reference8 articles.

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature;Rinella;J Hepatol,2023

2. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease;Estes;Hepatology,2018

3. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver;Newsome;J Hepatol,2023

4. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial;Loomba;Lancet Gastroenterol Hepatol,2023

5. Glucagon-like peptide-1 receptop agonist use in patients with liver cirrhosis and type 2 diabetes;Yen;Clinc Gastroenterol Hepatol,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP